Q2 2012 · —
Revenue$533.00K$533.00K no prior Q2 2011 on file+1,467.6% vs Q1 2012
Net income—
EPS Diluted-$2.37-$2.37 no prior Q2 2011 on fileN/M vs Q1 2012
Operating Income-$4,034,000—
Margins · derived
Operating margin-756.8%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q2 2011 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR